Two Sigma Advisers
CLRB icon

Two Sigma Advisers’s Cellectar Biosciences CLRB Stock Holding History

Two Sigma Advisers’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-447
Closed -$53.3K – 2476
2024
Q1 		$53.3K Buy
+447
New +$48.4K ﹤0.01% 2348
2022
Q2 		– Sell
-36
Closed -$7K – 2687
2022
Q1 		$7K Sell
36
-355
-91% -$62.1K ﹤0.01% 2704
2021
Q4 		$78K Buy
391
+192
+96% +$46.2K ﹤0.01% 2436
2021
Q3 		$55K Sell
199
-970
-83% -$296K ﹤0.01% 2365
2021
Q2 		$417K Sell
1,169
-980
-46% -$425K ﹤0.01% 2022
2021
Q1 		$1.04M Buy
+2,149
New +$1.28M ﹤0.01% 1635
2020
Q3 		– Sell
-184
Closed -$71K – 2429
2020
Q2 		$71K Buy
+184
New +$77.2K ﹤0.01% 2401

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's CLRB Position: Q2 2024 in Review

Two Sigma Advisers sold out of Cellectar Biosciences (CLRB) in Q2 2024, closing a stake of 447 shares — an estimated $53.3K sold.

Two Sigma Advisers first reported a position in CLRB in Q2 2020 and held it in 7 quarters. The position peaked at $1.04M in Q1 2021. 37 funds tracked by Wall St. Rank hold CLRB as of Q2 2024.

  • Two Sigma Advisers reported no remaining Cellectar Biosciences position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 447 Cellectar Biosciences shares in Q2 2024, an estimated $53.3K.
  • Two Sigma Advisers first reported a position in Cellectar Biosciences in Q2 2020 and held it in 7 quarters.
  • Two Sigma Advisers's Cellectar Biosciences position peaked at $1.04M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.